Evidence map›Paper›PMID 29567785›Full record

ArticleHaematologica2018

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Srdana Grgurevic, Patricia Montilla-Perez, Alice Bradbury, Julia Gilhodes, Sophie Queille, Sandrine Pelofy, Aurélien Bancaud, Thomas Filleron, Loïc Ysebaert, Christian Récher and 5 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Srdana GrgurevicCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France jean-sebastien.hoffmann@inserm.fr srdana.grgurevic@gmail.com.
Patricia Montilla-PerezCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France.
Alice BradburyUniversity of Newcastle, UK.
Julia GilhodesClinical Trials Office - Biostatistics Unit, Institute Claudius Regaud, Institute Universitaire du Cancer Toulouse-Oncopole (IUCT-O), Toulouse, France.
Sophie QueilleCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France.
Sandrine PelofyLAAS, Toulouse, France.
Aurélien BancaudLAAS, Toulouse, France.
Thomas FilleronClinical Trials Office - Biostatistics Unit, Institute Claudius Regaud, Institute Universitaire du Cancer Toulouse-Oncopole (IUCT-O), Toulouse, France.
Loïc YsebaertDepartment of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
Christian RécherDepartment of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
Guy LaurentDepartment of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
Jean-Jacques FourniéCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France.
Christophe CazauxCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France.
Anne Quillet-MaryCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France.
Jean-Sébastien HoffmannCRCT, Université de Toulouse, Inserm, CNRS, UPS, France; Equipe Labellisée Ligue Contre le Cancer, Laboratoire d'Excellence Toulouse Cancer, France jean-sebastien.hoffmann@inserm.fr srdana.grgurevic@gmail.com.
Centre de Recherche en Cancérologie de Toulouse · FRInstitut universitaire du cancer de Toulouse Oncopole · FRLaboratoire d'Analyse et d'Architecture des Systèmes · FRNewcastle University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alteration in the DNA replication, repair or recombination processes is a highly relevant mechanism of genomic instability. Despite genomic aberrations manifested in hematologic malignancies, such a defect as a source of biomarkers has been underexplored. Here, we investigated the prognostic value of expression of 82 genes involved in DNA replication-repair-recombination in a series of 99 patients with chronic lymphocytic leukemia without detectable 17p deletion or

Indexed as

Gene Expression Regulation, LeukemicAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDisease ProgressionDNA-Directed DNA PolymeraseDrug Resistance, NeoplasmGene Expression ProfilingHumansLeukemia, Lymphocytic, Chronic, B-CellMiceMutationPrognosisProportional Hazards ModelsTumor Suppressor Protein p53VidarabineDNA-Directed DNA PolymerasefludarabinePOLN protein, humanTumor Suppressor Protein p53Vidarabine

Identifiers

PMID29567785
PMCPMC6058778
OpenAlexW2793637808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.